Comparative Pharmacology
Head-to-head clinical analysis: CIS PYRO versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS PYRO versus QUADRAMET.
CIS-PYRO vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cis-pyro is not a recognized pharmaceutical agent. No mechanisms data available.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
Not applicable: CIS-PYRO is a pyrophosphate-based radiopharmaceutical used in cardiac imaging, not a therapeutic drug. Standard adult dose: 555-1110 MBq (15-30 mCi) intravenously once.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (IV); prolonged in renal impairment (up to 30 hours in ESRD).
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Primarily renal excretion: 65-80% unchanged in urine; biliary/fecal excretion accounts for 15-25%.
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical